Profil
Patrik Ringblom is currently an Independent Director at SpectraCure AB since 2025 and Head-Strategy & US Lead at Lakefront Biotherapeutics since 2023.
Formerly, Mr. Ringblom was VP-Rare Disease Novel Therapeutics & Alliance at Johnson & Johnson from 2022 to 2023.
Mr. Ringblom completed an MBA at Handelshögskolan i Göteborg.
Postes actifs de Patrik Ringblom
| Sociétés | Poste | Début |
|---|---|---|
| LAKEFRONT BIOTHERAPEUTICS NV | Corporate Officer/Principal | 01/10/2023 |
| SPECTRACURE AB | Directeur/Membre du Conseil | 01/01/2025 |
Anciens postes connus de Patrik Ringblom
| Sociétés | Poste | Fin |
|---|---|---|
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/10/2023 |
Formation de Patrik Ringblom
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Johnson & Johnson
Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
Galapagos NV
Galapagos NV BiotechnologyHealth Technology Manufactures and develops pharmaceutical products for oncology | Health Technology |
SpectraCure AB
SpectraCure AB Electronic Equipment/InstrumentsElectronic Technology Develops and provides equipment for cancer treatment | Electronic Technology |
Handelshögskolan i Göteborg
Handelshögskolan i Göteborg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















